# Safety and Immunogenicity of a Chimeric Recombinant Covid19 Vaccine SpiN-Tec MCTI UFMG

> **NCT07134725** · PHASE1,PHASE2 · COMPLETED · sponsor: **Federal University of Minas Gerais** · enrollment: 432 (actual)

## Conditions studied

- COVID - 19

## Interventions

- **BIOLOGICAL:** SpiN-Tec MCTI UFMG
- **OTHER:** Active Comparator: Covishield® vaccine
- **OTHER:** Active Comparator: Comirnaty® vaccine

## Key facts

- **NCT ID:** NCT07134725
- **Lead sponsor:** Federal University of Minas Gerais
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-23
- **Primary completion:** 2023-05-22
- **Final completion:** 2025-05-07
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07134725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07134725, "Safety and Immunogenicity of a Chimeric Recombinant Covid19 Vaccine SpiN-Tec MCTI UFMG". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07134725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*